Literature DB >> 27652201

Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?

Klaus Fenchel1, Stephen P Dale2, Wolfram C M Dempke3.   

Abstract

Entities:  

Year:  2016        PMID： 27652201      PMCID： PMC5009087          DOI： 10.21037/tlcr.2016.07.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Authors:  Jean-Charles Soria; Enriqueta Felip; Manuel Cobo; Shun Lu; Konstantinos Syrigos; Ki Hyeong Lee; Erdem Göker; Vassilis Georgoulias; Wei Li; Dolores Isla; Salih Z Guclu; Alessandro Morabito; Young J Min; Andrea Ardizzoni; Shirish M Gadgeel; Bushi Wang; Vikram K Chand; Glenwood D Goss
Journal:  Lancet Oncol       Date:  2015-07-05       Impact factor: 41.316

3.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Authors:  Martin Reck; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; Claudia-Nanette Gann; José Barrueco; Birgit Gaschler-Markefski; Silvia Novello
Journal:  Lancet Oncol       Date:  2014-01-09       Impact factor: 41.316

4.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

Review 5.  Targeted Therapy for NSCLC--A Double-edged Sword?

Authors:  Wolfram C M Dempke
Journal:  Anticancer Res       Date:  2015-05       Impact factor: 2.480

6.  Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Authors:  Li Zhang; Shenglin Ma; Xiangqun Song; Baohui Han; Ying Cheng; Cheng Huang; Shujun Yang; Xiaoqing Liu; Yunpeng Liu; Shun Lu; Jie Wang; Shucai Zhang; Caicun Zhou; Xiangwei Zhang; Nobuya Hayashi; Mengzhao Wang
Journal:  Lancet Oncol       Date:  2012-04-17       Impact factor: 41.316

7.  Overall survival in non-small cell lung cancer-what is clinically meaningful?

Authors:  Klaus Fenchel; Ludger Sellmann; Wolfram C M Dempke
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 8.  Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer.

Authors:  Joseph J Sacco; Hussein Al-Akhrass; Cornelia M Wilson
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 9.  Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?

Authors:  Wolfram C M Dempke; Ludger Sellmann; Klaus Fenchel; Klaus Edvardsen
Journal:  Anticancer Res       Date:  2015-11       Impact factor: 2.480

10.  The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Authors:  Lan-Ying Gou; An-Na Li; Jin-Ji Yang; Xu-Chao Zhang; Jian Su; Hong-Hong Yan; Zhi Xie; Na-Na Lou; Si-Yang Liu; Zhong-Yi Dong; Hong-Fei Gao; Qing Zhou; Wen-Zhao Zhong; Chong-Rui Xu; Yi-Long Wu
Journal:  Oncotarget       Date:  2016-08-09
View more
  3 in total

1.  Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints.

Authors:  Antonio Passaro; Filippo de Marinis
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Qiang Wu; Wuxia Luo; Wen Li; Ting Wang; Lin Huang; Feng Xu
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

Review 3.  Traveling With Cancer: A Guide for Oncologists in the Modern World.

Authors:  Sharon Heng; Brett Hughes; Michael Hibbert; Mustafa Khasraw; Zarnie Lwin
Journal:  J Glob Oncol       Date:  2019-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.